[go: up one dir, main page]

BRPI0412715A - células precursoras de oligodendrócitos e métodos de obter e cultivar as mesmas - Google Patents

células precursoras de oligodendrócitos e métodos de obter e cultivar as mesmas

Info

Publication number
BRPI0412715A
BRPI0412715A BRPI0412715-3A BRPI0412715A BRPI0412715A BR PI0412715 A BRPI0412715 A BR PI0412715A BR PI0412715 A BRPI0412715 A BR PI0412715A BR PI0412715 A BRPI0412715 A BR PI0412715A
Authority
BR
Brazil
Prior art keywords
methods
precursor cells
oligodendrocyte precursor
obtaining
population
Prior art date
Application number
BRPI0412715-3A
Other languages
English (en)
Inventor
Hiroshi Okazaki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0412715A publication Critical patent/BRPI0412715A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)

Abstract

"CéLULAS PRECURSORAS DE OLIGODENDRóCITOS E MéTODOS DE OBTER E CULTIVAR AS MESMAS". A presente invenção refere-se uma população fenotipicamente homogênea, de auto-renovação de células precursoras de oligodendrócitos tendo um estágio de desenvolvimento sincronizado e métodos de obtenção de uma população fenotipicamente homogênea, de auto-renovação de células precursoras de oligodendrócitos. Outros métodos incluem métodos de manutenção e armazenamento de uma população homogênea de células precursoras de oligodendrócitos durante um período de tempo prolongado sem mudança nas características das células e métodos de desdiferenciação de células precursoras de oligodendrócitos. A população fenotipicamente homogênea, de auto-renovação, de células precursoras de oligodendrócitos ou população homogênea de oligodendrócitos podem ser utilizáveis par ao tratamento de um paciente tendo uma condição ou distúrbio do sistema nervoso central.
BRPI0412715-3A 2003-07-18 2004-07-19 células precursoras de oligodendrócitos e métodos de obter e cultivar as mesmas BRPI0412715A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48793303P 2003-07-18 2003-07-18
PCT/IB2004/002670 WO2005007797A2 (en) 2003-07-18 2004-07-19 Oligodendrocyte precursor cells and methods of obtaining and culturing the same

Publications (1)

Publication Number Publication Date
BRPI0412715A true BRPI0412715A (pt) 2006-09-26

Family

ID=34079394

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412715-3A BRPI0412715A (pt) 2003-07-18 2004-07-19 células precursoras de oligodendrócitos e métodos de obter e cultivar as mesmas

Country Status (13)

Country Link
US (1) US20060172415A1 (pt)
EP (1) EP1646711A4 (pt)
JP (1) JP2007530001A (pt)
KR (1) KR20060037346A (pt)
CN (1) CN1833021A (pt)
AR (1) AR046076A1 (pt)
AU (1) AU2004257000B2 (pt)
BR (1) BRPI0412715A (pt)
CA (1) CA2532216A1 (pt)
MX (1) MXPA05014161A (pt)
SG (1) SG144166A1 (pt)
TW (1) TW200510537A (pt)
WO (1) WO2005007797A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846578A4 (en) * 2005-02-11 2010-02-10 Elan Pharm Inc GENE IDENTIFICATION METHODS THAT MODULATE MYELINISATION
KR20140132010A (ko) * 2005-06-23 2014-11-14 티슈진, 인코포레이티드 신경보호 효과 화합물
ES2323913B1 (es) * 2006-03-17 2010-05-14 Universidad De Salamanca (Titular Al 65%) Efecto mitogeno de sonic hedgehog (shh) sobre precursores de oligodendrocitos y su uso en enfermedades desmielinizantes.
US8168433B2 (en) * 2008-01-30 2012-05-01 Corning Incorporated Cell culture article and screening
JP5703028B2 (ja) * 2008-01-30 2015-04-15 アステリアス バイオセラピューティクス インコーポレイテッド 幹細胞由来オリゴデンドロサイト前駆細胞を培養するための合成表面
KR101809863B1 (ko) * 2008-01-30 2017-12-15 아스테리아스 바이오세라퓨틱스, 인크. 줄기 세포 유래 심근세포 배양용 합성 표면
EP2355826A1 (en) * 2008-11-07 2011-08-17 The Cleveland Clinic Foundation Compounds and methods of promoting oligodendrocyte precursor differentiation
CN105602889A (zh) * 2009-11-12 2016-05-25 Q医疗公司 用于哺乳动物来源的神经胶质限制性祖细胞的扩增、鉴定、表征和效能增强的方法和组合物
CN101735983B (zh) * 2009-12-29 2011-07-27 中国人民解放军第三军医大学 少突胶质前体细胞的分离纯化方法
ES2375860B8 (es) * 2010-03-31 2013-06-10 Fundación Hospital Nacional De Parapléjicos Para La Investigación Y La Integración (Fuhnpaiin) Método para la obtención de células precursoras de oligodendrocitos.
AU2012293276B2 (en) * 2011-08-07 2016-07-14 Kadimastem Ltd. Method of identifying agents that affect maturation, survival and myelination
KR101409336B1 (ko) 2012-02-15 2014-06-27 중앙대학교 산학협력단 희돌기교전구세포를 유효성분으로 포함하는 중추신경계 질환의 치료용 조성물
JP6000371B2 (ja) * 2012-03-27 2016-09-28 学校法人沖縄科学技術大学院大学学園 神経細胞培養用培地及びインビボ様シナプス形成増強神経細胞モデルの製造方法
JP6363096B2 (ja) * 2012-12-19 2018-07-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ミエリン形成をアッセイするためのマイクロピラーアレイ
CN103388007B (zh) * 2013-07-25 2016-08-24 宗兆文 一种利用真皮来源的间充质干细胞制备组织工程脊髓的方法
JP6844953B2 (ja) * 2015-04-22 2021-03-17 公益財団法人東京都医学総合研究所 アルツハイマー病研究を標的にしたグリア細胞システム
CN105062956B (zh) * 2015-08-21 2018-02-09 北京市虹天济神经科学研究院 人嗅粘膜嗅鞘细胞分离、传代、冻存、分化技术
CN105695409B (zh) * 2016-03-22 2019-09-27 中国人民解放军第二军医大学 一种裸鼹鼠少突胶质前体细胞培养方法
US11920155B2 (en) * 2016-03-30 2024-03-05 Asterias Biotherapeutics, Inc. Oligodendrocyte progenitor cell compositions
WO2018053210A1 (en) * 2016-09-14 2018-03-22 Asterias Biotherapeutics, Inc. Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
CN109722418B (zh) * 2017-10-29 2023-01-03 复旦大学 一种获取和纯化新生小鼠少突胶质前体细胞的方法
CN108624560B (zh) * 2018-06-01 2022-04-08 南京艾尔普再生医学科技有限公司 一种分化培养基及少突胶质前体细胞的制备方法
CN113481161A (zh) * 2021-07-30 2021-10-08 四川省医学科学院·四川省人民医院 一种培养基及少突胶质祖细胞的诱导培养方法以及应用
CN115340982A (zh) * 2022-08-23 2022-11-15 徐州医科大学 一种分离并纯化新生小鼠皮质区少突胶质前体细胞的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US6361996B1 (en) * 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
US6235527B1 (en) * 1997-11-29 2001-05-22 University Of Utah Research Foundation Lineage restricted glial precursors from the central nervous system
US6576464B2 (en) * 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
US20040029269A1 (en) * 2002-05-07 2004-02-12 Goldman Steven A Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

Also Published As

Publication number Publication date
TW200510537A (en) 2005-03-16
WO2005007797A2 (en) 2005-01-27
AU2004257000A1 (en) 2005-01-27
SG144166A1 (en) 2008-07-29
US20060172415A1 (en) 2006-08-03
AU2004257000B2 (en) 2011-07-21
CA2532216A1 (en) 2005-01-27
EP1646711A4 (en) 2008-03-19
JP2007530001A (ja) 2007-11-01
EP1646711A2 (en) 2006-04-19
WO2005007797A3 (en) 2006-05-11
KR20060037346A (ko) 2006-05-03
CN1833021A (zh) 2006-09-13
MXPA05014161A (es) 2006-05-25
AR046076A1 (es) 2005-11-23

Similar Documents

Publication Publication Date Title
BRPI0412715A (pt) células precursoras de oligodendrócitos e métodos de obter e cultivar as mesmas
GB2441939A (en) Surgical membrane
HUP0400371A2 (hu) Szén-monoxid alkalmazása szerv átültetés utáni túlélésének vagy működésének javítására alkalmas gyógyszerkészítmény előállítására
EP2277992A3 (en) Progenitor cells from Wharton's jelly of human umbilical cord
SG149061A1 (en) Definitive endoderm
BRPI0413007A (pt) bactéria escherichia, e, método de produzir l-lisina ou l-treonina
SG152273A1 (en) Pdx1 expressing endoderm
BRPI0410185A (pt) composição para manter a viabilidade de um orgão e célula
MX2009014273A (es) Metodos y composiciones para expansion e implantacion optimizadas de celulas madre mesenquimales.
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
MX2007005200A (es) Plaquetas a partir de celulas germinales.
WO2007030469A3 (en) Transplantable cell growth niche and related compositions and methods
SI1625212T1 (sl) Umeten imunski organ
AUPR540301A0 (en) A method of purification of cells
WO2005030040A8 (en) Hematopoietic stem cell identification and isolation
ATE420101T1 (de) Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
DE60032508D1 (de) VERFAHREN ZUR VERMEHRUNG VON NATüRLICHEN KILLERZELLEN
DE60313356D1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
WO2002098361A3 (en) T cell induced tissue repair and regeneration
WO2001042784A3 (en) Methods for screening compounds active on neurons
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
BRPI0403200A (pt) Método para recrescimento de células embriogênicas crioconservadas de conìferas
AU8478601A (en) Methods for culturing human lung mast cells and uses thereof
PL1687014T3 (pl) Zastosowanie dodatkowo przefermentowanego wywaru zbożowego do zapobiegania i/lub leczenia podwyższonych wartości cukru we krwi
WO2003044169A3 (en) Compositions and methods for reversibly inducing continual growth in normal cells

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2226 DE 03/09/2013.

B15K Others concerning applications: alteration of classification

Ipc: C12N 5/0797 (2010.01), C12N 5/079 (2010.01), A61K